9-Me-BC (9-Methyl-β-carboline) vs P-21
Side-by-side comparison of 9-Me-BC (9-Methyl-β-carboline) and P-21: mechanism, half-life, dose range, safety profile, and vendor pricing.
Price snapshot
9-Me-BC (9-Methyl-β-carboline)
P-21
9-Me-BC (9-Methyl-β-carboline)
9-Methyl--carboline (9-Me-BC) is a synthetic -carboline alkaloid that has drawn nootropic-community interest for a preclinical property that is genuinely unusual among -carbolines: in rodent and cell-culture studies it…
Lowest listed price: $54.99 across 1 listing
Full 9-Me-BC (9-Methyl-β-carboline) profileP-21
P-21 is a synthetic cyclic dipeptide — Cyclo(L-prolyl-glycine) — derived from the Selank/Semax C-terminal Pro-Gly-Pro motif. It was isolated and characterized by the Institute of Molecular Genetics at the Russian Academy…
No vendor price on file.
Full P-21 profileSide-by-side comparison
| Attribute | 9-Me-BC (9-Methyl-β-carboline) | P-21 |
|---|---|---|
| Category | Nootropics | Nootropic Peptide |
| Research Stage | Preclinical (rodent and cell-culture only) | Preclinical |
| Mechanism of Action | 9-Me-BC is a synthetic 9-methylated -carboline (pyridoindole) alkaloid. Unlike most -carbolines, which tend to be neurotoxic, 9-Me-BC shows a distinctive dopaminergic-supportive profile in preclinical models, acting through several linked mechanisms:… | Mechanism of action P021 (Peptide 021) is a small-molecule peptidomimetic derived by epitope mapping from the most active region of ciliary neurotrophic factor (CNTF). It is a linear N-acetylated tetrapeptide (Ac-Asp-Gly-Gly-Leu) capped with a C-terminal… |
| Half-Life | Not characterized in humans (no pharmacokinetic data). | Not formally characterized in published work. P021 has only been studied in rodents (oral/dietary and subcutaneous dosing); no human pharmacokinetic data exist. |
| Typical Dose Range | Community/anecdotal only: ~5-25 mg per day, oral. No validated or approved human dose exists. | — |
| Dosing Frequency | Typically once daily (morning) in community reports; frequently cycled rather than taken continuously. | — |
| Administration | — | — |
| Side Effects | No human safety data exist for 9-Me-BC, so there is no verified side-effect profile - the following are theoretical or anecdotal only. Community users most often report stimulation-type effects: insomnia if dosed late, anxiety or overstimulation, and headache.… | — |
| Molecular Weight | 182.22 g/mol (C12H10N2) | 578.7 g/mol (molecular formula C27H42N6O8; PubChem CID 56599151) |
| Common Vial Sizes | — | — |
Price tracking
9-Me-BC (9-Methyl-β-carboline): potential benefits
- Preclinical dopaminergic support: in rodent and cell-culture studies 9-Me-BC increased tyrosine hydroxylase expression and the number of differentiated dopamine neurons [PMID:17913302, PMID:20374418]
- Cognitive/learning signal in rodents: 10 days of dosing improved spatial learning and raised hippocampal dopamine with dendritic and synaptic growth in rats [PMID:22380576]
- Neuroprotective/neurorestorative in animal Parkinson's models: restored dopamine and substantia-nigra neuron counts after MPP+ injury and boosted mitochondrial complex I activity [PMID:20360614]
- Anti-inflammatory and neurotrophic actions in preclinical models: reduced microglial activation and induced neurotrophic factors such as BDNF, CDNF and artemin [PMID:20374418, PMID:32285253]
- Community-reported (anecdotal, unverified) motivation, drive, focus and mood lift - not demonstrated in any human study
P-21: potential benefits
- No structured benefit list published.
Frequently asked
What's the difference between 9-Me-BC (9-Methyl-β-carboline) and P-21?
9-Me-BC (9-Methyl-β-carboline) is a nootropics that 9-me-bc is a synthetic 9-methylated -carboline (pyridoindole) alkaloid. unlike most -carbolines, which tend to be neurotoxic, 9-me-bc shows a distinctive dopaminergic-supportive…. P-21 is a nootropic peptide that mechanism of action p021 (peptide 021) is a small-molecule peptidomimetic derived by epitope mapping from the most active region of ciliary neurotrophic factor (cntf). it is a…. The two differ in mechanism, half-life (Not characterized in humans (no pharmacokinetic data). vs Not formally characterized in published work. P021 has only been studied in rodents (oral/dietary and subcutaneous dosing); no human pharmacokinetic data exist.), and typical dose range.
Which has the longer half-life, 9-Me-BC (9-Methyl-β-carboline) or P-21?
9-Me-BC (9-Methyl-β-carboline) has a half-life of Not characterized in humans (no pharmacokinetic data).. P-21 has a half-life of Not formally characterized in published work. P021 has only been studied in rodents (oral/dietary and subcutaneous dosing); no human pharmacokinetic data exist.. Longer half-lives generally mean less frequent dosing but slower on/off kinetics.
Can you stack 9-Me-BC (9-Methyl-β-carboline) and P-21?
Stacking depends on mechanism overlap, safety profile, and goals. 9-Me-BC (9-Methyl-β-carboline) and P-21 should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds.
See current vendor prices
Listings from the vendors we track. Prices change often, so check the vendor before you buy.
Before you buy 9-Me-BC (9-Methyl-β-carboline) or P-21
Check the vendor trust score. Every supplier we track is rated 0-100 on COA verification, payment transparency, shipping, reviews, and listings: one published, reproducible methodology, applied to every vendor.
Related comparisons
Research use only. BodyHackGuide is a research and price-comparison reference. The compounds discussed on this page are not approved by the FDA for human consumption and are sold strictly for laboratory research. Prices shown are pulled from vendor listings tracked on BHG and are subject to change. We earn an affiliate commission on some outbound clicks, and every vendor is ranked on the same public, reproducible methodology. See editorial standards and affiliate disclosure.